Icario’s Medicaid Redetermination Solution Helps Plans Prepare & Guide Members to Maintain Coverage

Advisory Services Combined with Medicaid Outreach Expertise at Scale Enable Plans to Optimize Efforts From Start to Finish Across Their Enterprise While Localizing State-by-State Approaches

MINNEAPOLIS, Sept. 29, 2022 (GLOBE NEWSWIRE) — Icario, the healthcare industry’s largest health action company, today announced a Medicaid redetermination solution via its Icario Connect health action platform, providing Medicaid plans with a full suite of services to help plan and guide members through redetermination. Available now, the solution helps plans ensure that members don’t lose coverage when the COVID-19 public health emergency expires, benefiting health plan performance and overall member health and satisfaction.

Medicaid enrollment grew to more than 86 million members during the COVID-19 pandemic, with more than 15 million people gaining eligibility and disenrollment pausing during the public health emergency. The Department of Health and Human Services (HHS) is expected to extend the public health emergency for another 90 days in mid-October, but once it expires, between 5.3 million and 14.2 million people could lose Medicaid coverage.

Icario’s Medicaid redetermination solution helps plans avoid losing members with a combination of advisory research, guidance and recommendations, along with multi-channel outreach and education with its industry-leading member engagement platform.

“With nearly 30% of Medicaid members saying they either didn’t receive or don’t know if they received information about Medicaid redetermination, it’s on plans to educate their members to maintain plan performance and, more importantly, prevent members from losing the coverage they need,” said Troy Jelinek, chief commercial officer at Icario. “Our platform gives Medicaid plans all the tools and resources they need to ensure their members remain covered, which can also go a long way toward boosting member satisfaction levels.”

Icario Medicaid Redetermination: Key Benefits
Using the company’s industry-leading Icario Connect platform, the Medicaid redetermination solution is one of the industry’s only programs that helps guide members throughout the entire process. Key benefits include:

  • Full government program guidance: A complete Medicaid redetermination playbook, along with state-specific and CMS guidance and analysis, member engagement regulatory compliance, and rewards and incentives best practices
  • Industry insights and recommendations: Medicaid market research and best practices to develop a complete outreach strategy
  • Member research and program direction: Outreach and content optimization in multiple languages based on member location and preference
  • Contact information augmentation support: Enriched contact information to help mitigate member churn from out-of-date addresses, phone numbers, and other data

For more information on Medicaid redetermination, view the Icario webinar “Redetermination Strategies to Maximize Continuous Medicaid Coverage.” And for more information on the company’s health action capabilities, visit www.icariohealth.com.

About Icario
Icario is the leading health action company focused on connecting people to health. Icario uses pioneering behavioral research, data science, and our adaptive multi-channel platform to deliver personalization at scale for the most trusted healthcare organizations in all 50 states, including eight of the ten largest health plans. Learn more at www.icariohealth.com.

BOCA Communications for Icario
icario@bocacommunications.com

Staff

Recent Posts

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today…

31 minutes ago

Mexico’s EHR Revolution: Driving Digital Health Innovation and Market Growth, Insights From Black Book Research

Key Trends, Vendor Performance, and Opportunities Transforming Mexico's Healthcare IT Landscape MIAMI, FLORIDA / ACCESSWIRE…

31 minutes ago

Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees

Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

4 hours ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology…

4 hours ago

Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out

PITTSBURGH, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused…

4 hours ago

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

7 hours ago